Recent preclinical studies showed the potential of
nicotinamide adenine dinucleotide (
NAD(+)) precursors to increase oxidative phosphorylation and improve metabolic health, but human data are lacking. We hypothesize that the
nicotinic acid derivative
acipimox, an
NAD(+) precursor, would directly affect mitochondrial function independent of reductions in nonesterified
fatty acid (
NEFA) concentrations. In a multicenter randomized crossover trial, 21 patients with
type 2 diabetes (age 57.7 ± 1.1 years, BMI 33.4 ± 0.8 kg/m(2)) received either placebo or
acipimox 250 mg three times daily dosage for 2 weeks.
Acipimox treatment increased plasma
NEFA levels (759 ± 44 vs. 1,135 ± 97 μmol/L for placebo vs.
acipimox, P < 0.01) owing to a previously described rebound effect. As a result, skeletal muscle
lipid content increased and
insulin sensitivity decreased. Despite the elevated plasma
NEFA levels, ex vivo mitochondrial respiration in skeletal muscle increased. Subsequently, we showed that
acipimox treatment resulted in a robust elevation in expression of nuclear-encoded mitochondrial gene sets and a mitonuclear
protein imbalance, which may indicate activation of the mitochondrial unfolded protein response. Further studies in C2C12 myotubes confirmed a direct effect of
acipimox on
NAD(+) levels, mitonuclear
protein imbalance, and mitochondrial oxidative capacity. To the best of our knowledge, this study is the first to demonstrate that
NAD(+) boosters can also directly affect skeletal muscle mitochondrial function in humans.